The Systemic Immune-Inflammation Index Predicts Impaired Myocardial Perfusion and Short-Term Mortality in ST-Segment Elevation Myocardial Infarction Patients

Abstract

In this study, we aimed to evaluate the utility of the immune-inflammation index (SII) in estimating the no-reflow phenomenon and short-term cardiovascular prognosis in patients with ST-segment elevation myocardial infarction (STEMI). 723 consecutive patients with STEMI who underwent primary percutaneous coronary intervention (PCI) were enrolled in our study. The receiver-operating characteristics (ROC) curve was used to determine the cut-off value of SII to predict the no-reflow. The multivariate regression analysis analyzed the correlation between no-reflow and SII. The median value of SII was significantly higher in patients with no-reflow in comparison with normal reperfusion [1466 (939–2409) vs 905 (566–1379), p < .001]. The optimal threshold for SII in predicting the no-reflow phenomenon was 1036, with sensitivity and specificity of 70% and 59%, respectively. The area under the ROC curve (AUC) was 0.71 (95% CI, 0.66–0.75, p < .001). In multivariate analysis, SII ≥ 1036 value showed an independent predictive value for the no-reflow (OR = 0.51, 95% CI: 0.29–0.92, p = .02) and the 30-day cardiovascular mortality (OR = 2.37, 95% CI: 1.34–4.19, p = .003). Our results suggest that higher SII levels are independently associated with the no-reflow phenomenon and 30-day mortality in STEMI patients undergoing primary PCI.

High Systemic Immune-Inflammation Index and Body Mass Index Are Independent Risk Factors of the Thoracic Ossification of the Ligamentum Flavum

“…SII was introduced as an indicator of the systemic inflammatory status in the body and has attracted increasing attention from researchers [30]. SII can serve as a valuable index for predicting the clinical outcomes of human diseases, especially cancers [31][32][33]. High SII is associated with the poor prognosis of several types of cancer, such as bladder cancer [31], cervical cancer [34], oral cancer [35], gastric cancer [36], and breast cancer [36].…”

Prognostic value of systemic immune‐inflammation index in CAD patients: Systematic review and meta‐analyses

“…Bagci A et al 41 and Sayın MR et al 42 found that SII can independently predict new‐onset atrial fibrillation in patients with ACS. Liu Y et al 43 and Vatan MB et al 44 demonstrated the association of SII with slow flow phenomenon and no‐reflow phenomenon among STEMI patients undergoing primary PCI. We created Table 4 to display representative literature on the associations of SII with other CAD‐related adverse events in detail.…”

The Combined Effect of Systemic Immune-Inflammation Index and Type 2 Diabetes Mellitus on the Prognosis of Patients Undergoing Percutaneous Coronary Intervention: A Large-Scale Cohort Study

“… 10 , 11 Furthermore, SII has been identified as an independent predictor for poor clinical outcomes in patients with either stable CAD or acute coronary syndrome (ACS). 12 , 13 …”